Home Stock

Stock Research: Torrent Pharmaceuticals

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Torrent Pharmaceuticals

NSI:TORNTPHARM INE685A01028
23
  • Value
    8
  • Growth
    100
  • Safety
    Safety
    12
  • Combined
    4
  • Sentiment
    80
  • 360° View
    360° View
    23
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Torrent Pharmaceuticals Limited is an India-based company focused on pharmaceutical research, development, manufacturing, marketing, and distribution of branded and generic formulations. It operates in therapeutic segments including cardiovascular, central nervous system, gastrointestinal, anti-diabetes, pain management, gynecology, and dermatology, with brands like Tedibar and Macrotor. The company operates in India and internationally, with manufacturing facilities in Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh, and Sikkim. In the last fiscal year, the company had a market cap of $13620 million, profits of $1010 million, revenue of $1348 million, and 16107 employees.

more

ANALYSIS: With an Obermatt 360° View of 23 (better than 23% compared with alternatives), overall professional sentiment and financial characteristics for the stock Torrent Pharmaceuticals are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Torrent Pharmaceuticals. The consolidated Growth Rank has a good rank of 100, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 100% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 80, which means that professional investors are more optimistic about the stock than for 80% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 8, which means that the share price of Torrent Pharmaceuticals is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 92% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 12, which means that the company has a financing structure that is riskier than those of 88% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Price vs. Earnings (P/E)
Weakest Rank Growth
Country India
Industry Pharmaceuticals
Size Large
Website torrentpharma.com
Index
Torrent Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
8 13 21 39
Growth
100 89 77 15
Safety
Safety
12 5 1 1
Sentiment
80 43 88 77
360° View
360° View
23 17 37 9
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
70 40 63 51
Opinions Change
76 20 42 40
Pro Holdings
n/a 66 89 69
Market Pulse
46 42 71 65
Sentiment
80 43 88 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
8 13 21 39
Growth
100 89 77 15
Safety Safety
12 5 1 1
Combined
4 11 11 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
5 11 25 33
Price vs. Earnings (P/E)
1 19 22 33
Price vs. Book (P/B)
3 10 14 34
Dividend Yield
53 50 53 51
Value
8 13 21 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
88 78 63 56
Profit Growth
73 60 76 26
Capital Growth
100 74 35 4
Stock Returns
93 83 77 53
Growth
100 89 77 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
34 24 14 14
Refinancing
7 4 4 6
Liquidity
48 28 26 22
Safety Safety
12 5 1 1

Similar Stocks

Discover high‑ranked alternatives to Torrent Pharmaceuticals and broaden your portfolio horizons.

Kalbe Farma

JKT:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

SBI Life Insurance

NSI:SBILIFE
Country: India
Industry: Life & Health Insurance
Size: Large
Full Stock Analysis

Mega Lifesciences

SET:MEGA
Country: Thailand
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

CESC

NSI:CESC
Country: India
Industry: Electric Utilities
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews